---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121099"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:25:27.002751+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Beam reports initial BEAM-101 clinical data: engraftment, HbF >60%, one death from busulfan conditioning

## Summary
- BEAM-101 (sickle cell disease): 4 patients engrafted, median 17 days neutrophil, 20 days platelet; HbF >60% by month 1.
- BEAM-101: One death from respiratory failure attributed to busulfan conditioning, not BEAM-101; DSMC and FDA reviewed.
- BEAM-201 (T-ALL/T-LL): 2 of 3 patients achieved CRi/CR at doses <200 million cells; both eligible for stem cell transplant.
- ESCAPE NHP data: CD117 mAb conditioning well tolerated; HbF reached ~85% F-cells by 35 weeks in both animals.
- Initial data from BEACON trial also showed no VOCs post-treatment and normalization of hemolysis markers in all 4 evaluable patients.

## SEC filing metadata
- accession: 0000950170-24-121099
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017024121099/0000950170-24-121099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017024121099/beam-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121099
- JSON: https://secwatch.observer/filing/0000950170-24-121099.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.